Home / Tag Archives: hepatitis c

Tag Archives: hepatitis c

September, 2018

October, 2017

September, 2017

  • 29 September

    Merck Discontinues MK-3682B and MK-3682C Development Programs

    KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. This decision was made based on …

August, 2017

July, 2017

April, 2017

February, 2017

  • 22 February

    The 2017 Hepatitis C Treatment Landscape

    Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, particularly when it comes to direct-acting antiviral medications. This included various drug approvals and access improvements for hepatitis C medications, including Daklinza, Epclusa, Sovaldi/velpatasvir, Viekira, and Zepatier. As we make our way deeper into 2017, …